The challenge of diabetes continues to grow in Russia where 4 million people are diagnosed and even more are unaware of their condition. A new case study shows how Novo Nordisk together with partners is addressing this challenge and outlines the future potential for reducing the social and economic impact of diabetes in Russia.

Diabetes and its related complications negatively impact quality of life and represent a significant cost to the Russian society. Today, 40-50% of people with diabetes have a diabetes-related complication at the time of diagnosis, and 42% of the 12.5 billion US dollar annual cost of diabetes is associated with treating complications.[1]

Novo Nordisk’s latest Blueprint for Change case study, ‘Investing in diabetes care in Russia’, outlines the potential societal benefits that earlier detection and better control of diabetes[2] could lead to. This includes a significant reduction in complications, such as kidney failures and severe vision loss, thereby improving quality of life for people with the condition. On top of that, reducing complications could save society more than 1.5 billion US dollars in healthcare expenditures.

Read more: http://bit.ly/1yZa8Z2

© 2015 | 3BL Media/Novo Nordisk| All Rights Reserved